- Home
- SVM vs AUPH Comparison
SVM vs AUPH Comparison
Compare SVM & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVM
- AUPH
- Stock Information
- Founded
- SVM N/A
- AUPH 1993
- Country
- SVM Canada
- AUPH Canada
- Employees
- SVM N/A
- AUPH N/A
- Industry
- SVM Precious Metals
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- SVM Basic Materials
- AUPH Health Care
- Exchange
- SVM Nasdaq
- AUPH Nasdaq
- Market Cap
- SVM 906.7M
- AUPH 1.1B
- IPO Year
- SVM N/A
- AUPH 1999
- Fundamental
- Price
- SVM $4.65
- AUPH $7.58
- Analyst Decision
- SVM Strong Buy
- AUPH Strong Buy
- Analyst Count
- SVM 1
- AUPH 2
- Target Price
- SVM $6.75
- AUPH $11.50
- AVG Volume (30 Days)
- SVM 7.6M
- AUPH 1.6M
- Earning Date
- SVM 08-12-2025
- AUPH 07-31-2025
- Dividend Yield
- SVM 0.54%
- AUPH N/A
- EPS Growth
- SVM 40.00
- AUPH N/A
- EPS
- SVM 0.28
- AUPH 0.27
- Revenue
- SVM $298,895,000.00
- AUPH $247,295,000.00
- Revenue This Year
- SVM $1.10
- AUPH $12.15
- Revenue Next Year
- SVM $26.47
- AUPH $18.31
- P/E Ratio
- SVM $17.42
- AUPH $28.53
- Revenue Growth
- SVM 38.90
- AUPH 29.20
- 52 Week Low
- SVM $2.87
- AUPH $5.20
- 52 Week High
- SVM $5.32
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- SVM 65.21
- AUPH 40.36
- Support Level
- SVM $4.03
- AUPH $7.29
- Resistance Level
- SVM $4.22
- AUPH $8.86
- Average True Range (ATR)
- SVM 0.17
- AUPH 0.34
- MACD
- SVM 0.03
- AUPH -0.06
- Stochastic Oscillator
- SVM 97.14
- AUPH 19.37
About SVM Silvercorp Metals Inc.
Silvercorp Metals Inc is a mineral exploration company, engaged in the acquisition, exploration, development, and mining of mineral properties. The company's producing mines are located in China, and exploration and development projects are located in China and Ecuador. Its project portfolio comprises the El Domo copper-gold and the Condor gold project in Ecuador. In addition, it operates several silver-lead-zinc mines at the Ying Mining District in Henan Province, China, and the GC silver-lead-zinc mine in Guangdong Province, China. A majority of the company's revenue is generated through the sale of silver concentrates. Its reportable operating segments are the Ying Mining District and GC Mine in China, which derive maximum revenue, and the El Domo and Condor projects in Ecuador.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.